Indian Compulsory License Debate Enters New Phase With Push From Local Pharma Natco
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - In a move that could have far-reaching impact in determining India's approach to compulsory licensing, Natco Pharma - the local oncology and anti-HIV drugs specialist - has written to German drugs-to-agrochemicals giant Bayer to provide it with a "voluntary license" to manufacture and market its anti-cancer drug brand Nexavar (sorafenib)
You may also be interested in...
India Grants First Compulsory License To Natco For Bayer’s Nexavar; Disappointed, Bayer May Challenge Decision
India grants compulsory license to Natco for Bayer’s Nexavar; ruling could start run on more CLs.
India Grants First Compulsory License To Natco For Bayer’s Nexavar; Disappointed, Bayer May Challenge Decision
India grants compulsory license to Natco for Bayer’s Nexavar; ruling could start run on more CLs.
ViiV Healthcare Questions Natco's Ability To Make And Sell Selzentry In India; Stays Silent On Voluntary License Issue
MUMBAI - ViiV Healthcare - formed by GlaxoSmithKline Pharmaceuticals Plc and Pfizer Inc. in 2009 to work on a range of HIV/AIDS medications - struck back with a volley of questions to Natco Pharma Ltd., which had sought a voluntary license in December 2010 to manufacture generic versions of Selzentry